These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32700439)

  • 41. Nationwide Study of Factors Impacting Survival Outcome and Consequences in Children with Reactivation/Refractory Langerhans Cell Histiocytosis.
    Monsereenusorn C; Suwannaying K; Buaboonnam J; Sathitsamitphong L; Techavichit P; Pakakasama S; Chainansamit SO; Anurathapan U; Komvilaisak P; Traivaree C; Sanpakit K; Charoenkwan P; Seksarn P
    Asian Pac J Cancer Prev; 2024 May; 25(5):1831-1839. PubMed ID: 38809656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients.
    Stine KC; Saylors RL; Williams LL; Becton DL
    Med Pediatr Oncol; 1997 Oct; 29(4):288-92. PubMed ID: 9251735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group].
    Adam Z; Szturz P; Pour L; Krejčí M; Zahradová L; Tomíška M; Král Z; Koukalová R; Rehák Z; Mayer J
    Vnitr Lek; 2012 Jun; 58(6):455-65. PubMed ID: 22913238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Efficacy and safety of intermediate-dose cytarabine in the treatment of children with refractory high risk Langerhans cell histiocytosis].
    Wang WQ; Ge J; Ma HH; Lian HY; Cui L; Zhang L; Li ZG; Wang TY; Zhang R
    Zhonghua Er Ke Za Zhi; 2023 Dec; 61(12):1118-1123. PubMed ID: 38018049
    [No Abstract]   [Full Text] [Related]  

  • 45. Immune Thrombocytopenia in a Child With Refractory Langerhans Cell Histiocytosis Following Cladribine Containing Therapy.
    Lai CY; Pettit T
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):620-623. PubMed ID: 29889804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
    Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
    Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [MR-documented remission of pituitary stalk infiltration in patients with Langerhans cell histiocytosis following treatment with 2-chlorodeoxyadenosine].
    Vanícek J; Adam Z; Balsíková K; Krejcí M; Pour L; Szturz P; Zahradová L; Hájek R; Koukalová R; Rehák Z; Král Z; Mayer J
    Vnitr Lek; 2011 Oct; 57(10):871-5. PubMed ID: 22097697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.
    Héritier S; Barkaoui MA; Miron J; Thomas C; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Jeziorski E; Plat G; Aladjidi N; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Pagnier A; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Gandemer V; Martin-Duverneuil N; Taly V; Hélias-Rodzewicz Z; Emile JF; Hoang-Xuan K; Idbaih A; Donadieu J
    Br J Haematol; 2018 Nov; 183(4):608-617. PubMed ID: 30421536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment results of Langerhans cell histiocytosis with LSH II protocol].
    Mottl H; Ganevová M; Radvanská J; Chánová M; Smelhaus V; Kodet R; Mrhalová M; Tichý M
    Cas Lek Cesk; 2005; 144(11):753-5. PubMed ID: 16335702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco.
    Willis B; Ablin A; Weinberg V; Zoger S; Wara WM; Matthay KK
    J Clin Oncol; 1996 Jul; 14(7):2073-82. PubMed ID: 8683239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?
    Sedky MS; Rahman HA; Moussa E; Taha H; Raafat T; Hassanein O
    Indian J Pediatr; 2016 Mar; 83(3):214-9. PubMed ID: 26133729
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?
    Sedky MS; Hamouda A; Taha H; Zaky I; Hassanain O; El Hemaly A; ElHaddad A
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):635-643. PubMed ID: 30247183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine.
    Dimopoulos MA; Theodorakis M; Kostis E; Papadimitris C; Moulopoulos LA; Anastasiou-Nana M
    Leuk Lymphoma; 1997 Mar; 25(1-2):187-9. PubMed ID: 9130627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High risk Langerhans cell histiocytosis in children: the role of salvage in improving the outcome. A single center experience.
    Sedky MSM; Hamoda A; Taha H; Zaky I; Hassanain O; ElHaddad A
    Orphanet J Rare Dis; 2024 Jun; 19(1):242. PubMed ID: 38910253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.
    Bernard F; Thomas C; Bertrand Y; Munzer M; Landman Parker J; Ouache M; Colin VM; Perel Y; Chastagner P; Vermylen C; Donadieu J
    Eur J Cancer; 2005 Nov; 41(17):2682-9. PubMed ID: 16291085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cladribine for 13 cases refractory high-risk children Langerhans cell histiocytosis].
    Hu T; Liu R; Li J; Cao J; Zhang L; Li J; Fan W; Zhong D; Shi X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):985-9. PubMed ID: 25417874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulmonary Langerhans cell histiocytosis: a variable disease in childhood.
    Odame I; Li P; Lau L; Doda W; Noseworthy M; Babyn P; Weitzman S
    Pediatr Blood Cancer; 2006 Dec; 47(7):889-93. PubMed ID: 16276522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.